TABLE A5.
Baseline, D15, and Percentage of Change in SULmax Between pCR and No pCR in Patients With Residual Disease After Study Therapy and Subsequent Addition of Nonstudy Neoadjuvant Therapy
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.